Sanofi’s Sutimlimab Shows Promise In Rare Blood Disorder
First-In-Class Complement Pathway Inhibitor Impresses In Cold Agglutinin Disease
A Phase III rare-disease hit for Sanofi marks the first of a number of orphan drug read-outs expected in the coming year.
You may also be interested in...
The end of the year should see a flurry of new products reaching the market to break new commercial ground or shake up their respective therapeutic areas. Here, Scrip takes a look at 12 of the more interesting approvals expected in the coming months, with the help of analysts at Biomedtracker.
The tireless pace of change in hemato-oncology was showcased in Orlando.
The French drug maker is making a big splash into blood disorders with the $11.6bn acquisition of hemophilia specialist Bioverativ. Eloctate and Alprolix are young and growing brands, but the competition in hemophilia is fierce, which means Bioverativ's pipeline will also need to deliver to justify the premium price.